| abstract |
The present invention relates generally to immunoconjugates, and particularly to immunoconjugates comprising an interleukin-2 polypeptide mutant and an antibody that binds CD8. Furthermore, the present invention relates to polynucleotide molecules encoding such immunoconjugates, as well as vectors and host cells comprising such polynucleotide molecules. The present invention further relates to methods for producing said mutant immunoconjugates, pharmaceutical compositions comprising said mutant immunoconjugates, and uses thereof. |